Highlights Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-30 am EDT			5-day change	1st Jan Change
4,153 ^JPY	+1.57%		+0.75%	+2.44%

09:41am	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	RE
Apr. 26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	03:41am	RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	Apr. 26	MT
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	Apr. 26	MT
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	Apr. 26	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	Apr. 18	CI
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	Apr. 15	MT
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	Mar. 31	CI
Final dividend	Mar. 27	FA
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder	Mar. 26	MT
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	Mar. 26	CI
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	Mar. 20	MT
Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type	Mar. 19	MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	Mar. 19	MT
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® in Adult Patients with Newly Diagnosed Ph+ ALL	Mar. 19	CI
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia	Mar. 13	CI
India's Serum looks beyond COVID with new vaccines for malaria, dengue	Mar. 10	RE
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Highlights

Filters